| Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis G Caocci, O Mulas, D Mantovani, A Costa, A Galizia, L Barabino, M Greco, ... Annals of Hematology 101 (4), 929-931, 2022 | 20 | 2022 |
| Chronic graft vs. host disease and hypogammaglobulinemia predict a lower immunological response to the BNT162b2 mRNA COVID-19 vaccine after allogeneic hematopoietic stem cell … L Barabino, A Galitzia, R Murru, G Caocci, C Targhetta, M Greco, ... European Review for Medical & Pharmacological Sciences 26 (23), 2022 | 4 | 2022 |
| Patients with chronic lymphocytic leukemia have a very high risk of ineffective response to the BNT162b2 vaccine A Galitzia, L Barabino, R Murru, G Caocci, M Greco, G Angioni, O Mulas, ... Vaccines 10 (7), 1162, 2022 | 4 | 2022 |
| Should be a third dose of BNT162b2 mRNA COVID-19-vaccine administered in patients with myelofibrosis under ruxolitinib? G Caocci, O Mulas, D Mantovani, A Costa, A Galizia, L Barabino, M Greco, ... Blood 138, 2573, 2021 | 2 | 2021 |
| PB1894 INFECTIOUS RISK AND HYPOGAMMAGLOBULINEMIA IN A MONOCENTRIC REAL LIFE COHORT OF 211 CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS FOLLOWED FOR 25 YEARS R Murru, G Caocci, A Galitzia, S Uda, F Culurgioni, S Oppi, G La Nasa HemaSphere 3 (S1), 863, 2019 | 2 | 2019 |
| Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY T Chatzikonstantinou, L Scarfò, G Karakatsoulis, E Minga, D Chamou, ... EClinicalMedicine 65, 2023 | 1 | 2023 |
| Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia AM Frustaci, G Del Poeta, A Visentin, P Sportoletti, A Fresa, C Vitale, ... Therapeutic Advances in Hematology 13, 20406207221127550, 2022 | 1 | 2022 |
| Prediction of severe infections in chronic lymphocytic leukemia: a simple risk score to stratify patients at diagnosis R Murru, A Galitzia, L Barabino, R Presicci, G La Nasa, G Caocci Annals of Hematology, 1-10, 2024 | | 2024 |
| Kinetics of Lymphocytosis during First-Line Treatment with BTK Covalent Inhibitors in Chronic Lymphocytic Leukemia Patients: An Italian Multicenter Experience of Real Life I Innocenti, A Mosca, A Tomasso, A Galitzia, L Scarfo, E Galli, R Laureana, ... Blood 142, 6545, 2023 | | 2023 |
| Real-World Venetoclax-Obinutuzumab in 232 Treatment Naive CLL Patients: Feasibility and Tolerability A Tedeschi, A Galitzia, A Frustaci, C Patti, A Sanna, L Appio, L Schiattone, ... Blood 142, 4646, 2023 | | 2023 |
| PB1942: PARTIAL RESPONSE WITH LYMPHOCYTOSIS (PR-L) IS NOT APPLICABLE FOR ACALABRUTINIB. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE. I Innocenti, A Mosca, A Tomasso, A Galitzia, L Scarfò, E Galli, R Laureana, ... HemaSphere 7 (S3), e83737e4, 2023 | | 2023 |
| S149: OTHER MALIGNANCIES IN THE HISTORY OF CLL: THE FINAL ANALYSIS OF THE INTERNATIONAL MULTICENTER STUDY CONDUCTED BY ERIC, IN HARMONY. T Chatzikonstantinou, L Scarfò, G Karakatsoulis, E Minga, D Chamou, ... HemaSphere 7, e24596f8, 2023 | | 2023 |
| Three is better than two: humoral response in allogeneic HSCT after the third BNT162b2 SARS-CoV-2 mRNA vaccine L Barabino, A Galitzia, R Murru, G Caocci, M Greco, C Targhetta, ... Eur Rev Med Pharmacol Sci 27 (15), 6914-6916, 2023 | | 2023 |
| Myeloma’s multiple morphologies S Cantoni, A Galitzia, V Mancini, AM Cafro, R Cairoli Ejhaem, 2023 | | 2023 |
| Clinical course and features of persistent polyclonal B-cell lymphocytosis with BCL-6 amplification during pregnancy A Galitzia, R Murru, G Caocci, L Barabino, A Azzena, VM Licheri, M Greco, ... European Review for Medical and Pharmacological Sciences 27 (8), 3514-3518, 2023 | | 2023 |
| Immune Response to Covid-19 Vaccination in Patients with Chronic Lymphocytic Leukaemia (CLL): An Experience from Two Italian Centres I Innocenti, R Murru, G Benintende, A Galitzia, A Mosca, L Barabino, ... Blood 140 (Supplement 1), 12407-12409, 2022 | | 2022 |
| Infection Risk Evaluation Based on a Novel Scoring System in Chronic Lymphocytic Leukemia (CLL) Patients at Diagnosis R Murru, A Galitzia, G Caocci, L Barabino, R Presicci, F Culurgioni, ... Blood 140 (Supplement 1), 4144-4145, 2022 | | 2022 |
| GENOMIC MUTATION PROFILE IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): RESULTS FROM A REGIONAL CLINICAL RESEARCH PROJECT BASED ON TARGETED NEXT GENERATION SEQUENCING R Murru, G Piras, S Uda, M Monne, A Galitzia, P Uva, R Cusano, ... HAEMATOLOGICA 107, 33-33, 2022 | | 2022 |
| GENE MUTATIONS ANALYSIS AND NEW INSIGHTS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PRELIMINARY RESULTS FROM A CLINICAL RESEARCH PROJECT BASED ON NEXT GENERATION SEQUENCING (NGS) R Murru, G Piras, S Uda, M Monne, A Galitzia, P Uva, R Cusano, ... Age 65, 55, 2020 | | 2020 |
| COMBINATED ANTIBODY DEFICIENCY AND INFECTIOUS FREE SURVIVAL IN HYPOGAMMAGLOBULINEMIA PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A LONG TERM FOLLOW UP MONOCENTRIC REAL … R Murru, G Caocci, A Galitzia, S Uda, F Culurgioni, S Oppi, G La Nasa HAEMATOLOGICA 104, 100-101, 2019 | | 2019 |
Luca BarabinoDepartment of Medical Sciences and Public Health, Hematology and HSCT Unit, ARNAS G. BrotzuVerified email at studenti.unica.it
